191 related articles for article (PubMed ID: 33560717)
21. Accuracy of 68Ga-PSMA PET-CT and PET-MRI in lymph node staging for localized prostate cancer.
Barbosa ÁRG; Amaral BS; Lourenço DB; Bianco B; Gushiken FA; Apezzato M; Silva JF; Cunha MLD; Filippi RZ; Baroni RH; Lemos GC; Carneiro A
Einstein (Sao Paulo); 2022; 20():eAO6599. PubMed ID: 35584444
[TBL] [Abstract][Full Text] [Related]
22. Assessment of volumetric parameters derived from 68Ga-PSMA PET/CT in prostate cancer patients with biochemical recurrence: an institutional experience.
Okudan B; Coşkun N; Seven B; Atalay MA; Yildirim A; Görtan FA
Nucl Med Commun; 2021 Nov; 42(11):1254-1260. PubMed ID: 34284438
[TBL] [Abstract][Full Text] [Related]
23.
Klingenberg S; Jochumsen MR; Ulhøi BP; Fredsøe J; Sørensen KD; Borre M; Bouchelouche K
J Nucl Med; 2021 Feb; 62(2):214-220. PubMed ID: 32444374
[TBL] [Abstract][Full Text] [Related]
24. Comparison of the diagnostic utility of 99mTc-PSMA scintigraphy versus 68Ga-PSMA-11 PET/CT in the detection of metastatic prostate cancer and dosimetry analysis: a gamma-camera-based alternate prostate-specific membrane antigen imaging modality.
Singh B; Sharma S; Bansal P; Hooda M; Singh H; Parihar AS; Kumar A; Watts A; Mohan R; Singh SK
Nucl Med Commun; 2021 May; 42(5):482-489. PubMed ID: 33395191
[TBL] [Abstract][Full Text] [Related]
25. Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer.
van Leeuwen PJ; Emmett L; Ho B; Delprado W; Ting F; Nguyen Q; Stricker PD
BJU Int; 2017 Feb; 119(2):209-215. PubMed ID: 27207581
[TBL] [Abstract][Full Text] [Related]
26. Initial Experience with Volumetric
Schmuck S; von Klot CA; Henkenberens C; Sohns JM; Christiansen H; Wester HJ; Ross TL; Bengel FM; Derlin T
J Nucl Med; 2017 Dec; 58(12):1962-1968. PubMed ID: 28522740
[TBL] [Abstract][Full Text] [Related]
27. The role of histopathological and biochemical parameters for predicting metastatic disease on
Aydos U; Çetin S; Akdemir ÜÖ; Budak FÇ; Ateş SG; Koparal MY; Gönül İI; Gülbahar Ö; Sözen S; Atay LÖ
Prostate; 2021 Dec; 81(16):1337-1348. PubMed ID: 34516677
[TBL] [Abstract][Full Text] [Related]
28. Findings in 1,123 Men with Preoperative
Raveenthiran S; Yaxley WJ; Franklin T; Coughlin G; Roberts M; Gianduzzo T; Kua B; Samaratunga H; Delahunt B; Egevad L; Wong D; McEwan L; Brown N; Parkinson R; Esler R; Yaxley JW
J Urol; 2022 Mar; 207(3):573-580. PubMed ID: 34694140
[TBL] [Abstract][Full Text] [Related]
29. Risk of metastatic disease on
Yaxley JW; Raveenthiran S; Nouhaud FX; Samaratunga H; Yaxley WJ; Coughlin G; Yaxley AJ; Gianduzzo T; Kua B; McEwan L; Wong D
BJU Int; 2019 Sep; 124(3):401-407. PubMed ID: 31141284
[TBL] [Abstract][Full Text] [Related]
30. 68Ga-PSMA-11 PET/CT in Newly Diagnosed Prostate Adenocarcinoma.
Ergül N; Yilmaz Güneş B; Yücetaş U; Toktaş MG; Çermik TF
Clin Nucl Med; 2018 Dec; 43(12):e422-e427. PubMed ID: 30273204
[TBL] [Abstract][Full Text] [Related]
31. Incremental Impact of [
Szigeti F; Schweighofer-Zwink G; Meissnitzer M; Hauser-Kronberger C; Hitzl W; Kunit T; Forstner R; Pirich C; Beheshti M
Mol Imaging Biol; 2022 Feb; 24(1):50-59. PubMed ID: 34519966
[TBL] [Abstract][Full Text] [Related]
32.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
33. Pilot study comparing dominant intraprostatic lesion volume using Ga-68 prostate-specific membrane antigen PET-computed tomography and multiparametric MRI.
Sasidharan A; Murthy V; Natarajan A; Agarwal A; Ranagrajan V; Gudi S; Singh S; Popat P
Nucl Med Commun; 2020 Dec; 41(12):1291-1298. PubMed ID: 32941400
[TBL] [Abstract][Full Text] [Related]
34.
Uprimny C; Kroiss AS; Decristoforo C; Fritz J; von Guggenberg E; Kendler D; Scarpa L; di Santo G; Roig LG; Maffey-Steffan J; Horninger W; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):941-949. PubMed ID: 28138747
[TBL] [Abstract][Full Text] [Related]
35. Significance of metabolic tumor volume and total lesion uptake measured using Ga-68 labelled prostate-specific membrane antigen PET/CT in primary staging of prostate cancer.
Kubilay E; Akpinar Ç; Oǧuz ES; Araz MS; Soydal Ç; Baltacı S; Ürün Y; Süer E
Urol Oncol; 2022 Sep; 40(9):408.e19-408.e25. PubMed ID: 35902300
[TBL] [Abstract][Full Text] [Related]
36. 99mTc-PSMA SPECT/CT Versus 68Ga-PSMA PET/CT in the Evaluation of Metastatic Prostate Cancer.
Fallahi B; Khademi N; Karamzade-Ziarati N; Fard-Esfahani A; Emami-Ardekani A; Farzanefar S; Eftekhari M; Beiki D
Clin Nucl Med; 2021 Feb; 46(2):e68-e74. PubMed ID: 33234922
[TBL] [Abstract][Full Text] [Related]
37. Dual-phase 68Ga-PSMA-11 PET/CT may increase the rate of detected lesions in prostate cancer patients.
Dadgar H; Seyedi Vafaee M; Norouzbeigi N; Jafari E; Gholamrezanezhad A; Assadi M
Urologia; 2021 Nov; 88(4):355-361. PubMed ID: 33627056
[TBL] [Abstract][Full Text] [Related]
38. Clinical parameters and nomograms for predicting lymph node metastasis detected with
Onal C; Ozyigit G; Oymak E; Guler OC; Hurmuz P; Tilki B; Reyhan M; Tuncel M; Akyol F
Prostate; 2021 Jul; 81(10):648-656. PubMed ID: 33949694
[TBL] [Abstract][Full Text] [Related]
39. The role of Ga
Erdogan M; Sengul SS; Cetin B; Avcı M; Yagci S; Ozkoç I; Barikan DE; Yildiz M
Ann Nucl Med; 2022 Jun; 36(6):562-569. PubMed ID: 35397091
[TBL] [Abstract][Full Text] [Related]
40. Role of
Can C; Gündoğan C; Yildirim OA; Poyraz K; Güzel Y; Kömek H
Hell J Nucl Med; 2021; 24(1):25-35. PubMed ID: 33866336
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
